OncoMatch/Clinical Trials/NCT06424665
A Study of FZ-AD005 in Patients With Advanced Solid Tumors
Is NCT06424665 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies FZ-AD005 for advanced solid tumor, sclc(small cell lung cancer) or lcnec (large cell neuroendocrine carcinoma).
Treatment: FZ-AD005 — A First-in-Human, Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with Advanced Solid Tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Small Cell Lung Cancer
Tumor Agnostic
Disease stage
Metastatic disease required
advanced solid tumors ( especially SCLC or LCNEC); Have measurable lesions defined in RECIST v. 1.1
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: anti-DLL3 antibody
previous treatment with any anti-DLL3 antibody
Cannot have received: other anti-tumor treatments
receiving other anti-tumor treatments within 4 weeks prior to the first dose
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06424665 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-DLL3 antibody, other anti-tumor treatments disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages